Vanda Pharmaceuticals expands board to seven, appoints Charles C. Duncan as director

Filed April 22, 2026 · Period ending April 22, 2026 · ~1 min read

Key Changes

• medium

  Board expanded from six to seven members and appointed Charles C. Duncan, Ph.D., as independent Class II director with term expiring at 2026 annual meeting. Duncan meets SEC and Nasdaq independence standards.

  Item 5.02 verify on EDGAR →
• low

  Duncan receives $390,000 initial restricted stock unit grant vesting in four equal annual installments starting April 2027, plus $50,000 annual cash fee paid quarterly. All RSUs accelerate upon change of control.

  Item 5.02 verify on EDGAR →
• low

  Duncan eligible for annual RSU grants valued at $260,000 after each stockholder meeting starting 2026, vesting after one year or immediately upon change of control.

  Item 5.02 verify on EDGAR →